Literature DB >> 25435733

Prevalence of Alloimmunization to Human Platelet Antigen Glycoproteins and Human Leucocyte Antigen Class I in β Thalassemia Major Patients in Western India.

Joseph Philip1, Sudeep Kumar1, T Chatterjee1, R S Mallhi1.   

Abstract

Present management of β thalassemia major by regular packed red blood cell (PRBC) transfusions poses risk of alloimmunization not only to red blood cell antigens, but also to human platelet antigens (HPA) and Human leucocyte antigens class I (HLA I). However data in this context is very limited in Indian population. The aim of the study was to determine the prevalence of alloimmunization to HPA and HLA I in β thalassemia major patients who have received multiple PRBC transfusions over the years. A cross sectional study was performed at our tertiary care blood bank. β thalassemia major patients of more than 6 years of age were included who were receiving fresh, leucoreduced and irradiated PRBC units regularly with annual requirement of more than ten PRBC transfusions. A total of 9 out of 80 (11.25 %) patients were found to be alloimmunized for HPA antigens of various specificity and 24 out of 80 (30 %) developed antibodies to HLA I. The awareness of development of alloimmunization to HPA and HLA antigens in multi PRBC transfused thalassemics, despite use of leucofilters will prompt us, to look for improvement in our current PRBC preparations to minimise platelet alloimmunisation. Further studies are required to validate the findings and build the base line data in this regard. This is of importance, especially in view of providing suitable cross-matched platelets when required in future especially when considering future haematopoietic stem cell transplantation (HSCT).

Entities:  

Keywords:  Anti-human leucocyte antigens; Anti-human platelet antigens; Haematopoietic stem cell transplantation; Packed red blood cell concentration

Year:  2013        PMID: 25435733      PMCID: PMC4243396          DOI: 10.1007/s12288-013-0297-5

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  10 in total

1.  Frequency distribution of antigens in the human platelet antigen-1 system in the western Indian population.

Authors:  Bipin Kulkarni; Dipika Mohanty; K Ghosh; Aruna Pawar; Amit Khare
Journal:  Transfusion       Date:  2002-03       Impact factor: 3.157

2.  RBC alloimmunization in blood transfusion-dependent beta-thalassemia patients in southern Iran.

Authors:  M Karimi; P Nikrooz; S Kashef; N Jamalian; Z Davatolhagh
Journal:  Int J Lab Hematol       Date:  2007-10       Impact factor: 2.877

3.  Alloimmunization to platelets in heavily transfused patients with sickle cell disease.

Authors:  D F Friedman; M B Lukas; A Jawad; P J Larson; K Ohene-Frempong; C S Manno
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

4.  Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.

Authors:  Meenu Bajpai; Babita Kaura; Neelam Marwaha; Savita Kumari; R R Sharma; S K Agnihotri
Journal:  Natl Med J India       Date:  2005 May-Jun       Impact factor: 0.537

5.  Screening for platelet antibodies in adult idiopathic thrombocytopenic purpura: a comparative study using solid phase red cell adherence assay and flow cytometry.

Authors:  Jeong-Shi Lin; Jau-Yi Lyou; Ying-Ju Chen; Pei-Shan Chen; Hsueng-Mei Liu; Chao-Hung Ho; Tsung-Chi Hao; Cheng-Hwai Tzeng
Journal:  J Chin Med Assoc       Date:  2006-12       Impact factor: 2.743

6.  Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients.

Authors:  Shyh-Chyi Lo; Jhy-Sheng Chang; Susannah Whay-Sue Lin; Dong-Tsamn Lin
Journal:  Transfusion       Date:  2005-05       Impact factor: 3.157

7.  Alloimmunization and erythrocyte autoimmunization in transfusion-dependent Egyptian thalassemic patients.

Authors:  Dalia A Saied; Ahmed M Kaddah; Reem M Badr Eldin; Safaa S Mohaseb
Journal:  J Pediatr Hematol Oncol       Date:  2011-08       Impact factor: 1.289

8.  Alloimmunization against human platelet antigen 2 (HPA2) in a series of multi-transfused beta-thalassemia patients.

Authors:  P L Tazzari; F Ricci; C Tassi; A Bontadini; F Fruet; R Conte
Journal:  Haematologica       Date:  1998-08       Impact factor: 9.941

9.  Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation.

Authors:  Sarah Marktel; Sara Napolitano; Elisabetta Zino; Barbara Cappelli; Robert Chiesa; Francesca Poli; Roberto Crocchiolo; Paola Ronchi; Silvano Rossini; Fabio Ciceri; Maria G Roncarolo; Katharina Fleischhauer
Journal:  Pediatr Transplant       Date:  2010-01-07

10.  Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).

Authors:  Arun P Wiita; Ashok Nambiar
Journal:  Transfusion       Date:  2012-03-12       Impact factor: 3.157

  10 in total
  2 in total

1.  Frequency of Platelet Crossmatch Positivity and Predictive Value for Poor Platelet Increment Among Paediatric Oncohaematology Patients in India.

Authors:  Simon Kingsley; Mary Purna Chacko; P Amal; Grace Rebekah; G Mathew Leni; Daniel Dolly
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-25       Impact factor: 0.900

2.  Evaluation of Human Leucocyte Antigen Mediated Platelet Transfusion Refractoriness and Platelet Crossmatching Assay in Patients with Hematologic Disorders.

Authors:  Wafaa A Neanaey; Akram A Deghady; Dalia A Nafea; Nada M Fahmy; Asmaa M Gouda
Journal:  Oman Med J       Date:  2022-07-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.